Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data SCYNEXIS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.26
0.26
0.26
0.12
0
13.2
5.09
140
3.75
20.6
Research and development
20.1
18.3
21.6
38.4
36.5
23.8
27.3
30.9
26.4
22.3
Selling, general and administrative
8
8.25
8.68
10.6
14.6
49.9
63
20.9
14.5
14.4
Operating expenses
28.1
26.6
30.2
49
51.1
74
90.8
67.5
40.9
36.7
Operating income
-27.8
-26.3
-30
-48.9
-51.1
-60.8
-85.8
72.7
-37.1
-16.1
Interest expense
0.35
1.46
1.63
0.99
1.18
2.66
5.2
3.13
0.83
0.17
Interest income
0.19
0.39
0.97
0.81
0.19
0.02
1.42
3.95
4.29
2.18
Other non-operating income
-2.17
1.26
10.8
-4.79
-7.18
24.9
18.2
-5.49
16
7.47
Pre-tax income
-30
-25.1
-19.2
-53.7
-58.3
-36
-67.5
67.2
-21.1
-8.61
Income tax
0
0
-6.74
0
-3.15
-3.09
-4.7
0.14
0.15
0
Income from continuing operations
-30
Net income
-30
-25.1
-12.5
-53.7
-55.2
-32.9
-62.8
67
-21.3
-8.61
EBITDA
-27.8
-26.3
-29.9
-48.8
-51
-60.5
-85.2
73.2
-37.1
EPS, basic
-1.58
-1.25
-1.47
1.40
-0.44
-0.17
EPS, diluted
-1.58
-1.25
-1.47
1.39
-0.44
-0.17
Shares, basic (weighted)
19
26.7
43.9
5.61
10.7
26.4
42.6
47.9
48.5
49.9
Shares, diluted (weighted)
19
26.7
43.9
5.61
10.7
26.4
42.6
48.4
48.5
49.9
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
35.7
11.5
11.4
41.9
93
104
45.8
34.1
16.1
21.3
Short-term investments
22.9
0
27.7
40.3
43.2
18.8
Receivables
0
0.86
2.1
0
Inventory
0
0.46
0.9
0
Other current assets
0.04
0.09
0.05
0.67
0.37
0
0.06
4.91
1.23
0.02
Total current assets
59.3
45
51.5
52.4
98.2
109
79.1
102
72.2
40.4
Property, plant and equipment
0
0.52
0.41
0.3
0.11
Lease right-of-use assets
0
3.19
3
2.8
2.59
2.36
2.09
1.76
Intangible assets
0
1.06
0.41
0
Other non-current assets
0.12
0.57
0.81
0.81
0.57
6.24
5.51
0
Total assets
59.8
45.9
53.2
57.2
103
120
87.8
128
90.6
59
Accounts payable
2.19
3.83
3.65
7.18
4.64
7.85
5.94
7.15
4.57
2.23
Accrued liabilities
1.27
1.71
2.1
3.8
4.14
5.7
5.63
7.5
3.79
2.79
Deferred revenue
0.26
0.26
0.12
0
0
1.19
1.64
0.24
Short-term debt
0
4.35
0
0
Total current liabilities
3.72
10.1
5.88
11
26.4
13.6
17.6
16.3
24.1
5.73
Long-term debt
14.3
10.3
15.1
0
Lease liabilities
0
3.33
3.27
3.2
2.92
2.58
2.18
1.69
Other non-current liabilities
0
3.35
0
Total liabilities
25
24.4
21.9
44.3
79.8
78.6
84.6
55.5
35.6
9.65
Total debt
14.3
14.7
15.1
0
34.4
Paid-in capital
215
227
249
284
349
401
425
428
432
435
Retained earnings
-180
-205
-218
-271
-327
-359
-422
-355
-377
-385
Shareholders' equity
34.8
21.4
31.2
12.9
22.8
41.3
3.23
73
55.1
49.4
Total equity
34.8
21.4
31.2
12.9
22.8
41.3
3.23
73
55.1
49.4
Total liabilities and equity
59.8
45.9
53.2
57.2
103
120
87.8
128
90.6
59
Shares outstanding
24.6
29
48
9.74
19.7
28.7
32.7
37.2
38
5.44
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-30
-25.1
-12.5
-53.7
-55.2
-32.9
-62.8
67
-21.3
-8.61
Depreciation and amortization
0.03
0.04
0.05
0.11
0.11
0.38
0.61
0.58
0
Stock-based compensation
1.21
1.66
1.82
1.83
2.22
2.09
3.69
2.62
3.35
2.85
Change in receivables
0
0
-0.86
-1.24
2.1
0
Change in inventory
0
-5.29
-0.44
-8.85
0
Change in payables
-0.31
2.08
0.22
5.22
-2.6
2.76
-1.48
1.17
-2.65
-2.23
Cash from operations
-29.4
-24.6
-28.3
-38.1
-49.4
-54.6
-79.9
60.2
-24
-5.28
Capital expenditures
-0.03
-0
-0.57
0
-0
0
Purchases of investments
0
Sales and maturities of investments
12.3
68.8
84.9
65.7
20.7
0
Cash from investing
-22.5
-9.62
-0.8
26.2
6.47
-1.17
-27.4
-34.9
6.15
24.3
Debt repaid
0
0
-16
0
Stock issued
28.1
10.3
31.7
46.3
90.6
38.6
47.2
0
0
0.01
Cash from financing
40.5
9.99
29.4
42.3
94
67.1
48.6
-36.7
-0.14
-14.2
Net change in cash
-11.3
-24.2
0.3
30.4
51.1
11.4
-58.7
-11.4
-18
4.85
Free cash flow
-29.4
-24.6
-28.9
-38.1
-49.4
-54.6
Interest paid
0.35
1.46
1.62
0.85
1.09
2.26
5.19
3.25
0.84
0.42
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.39 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-117.7%
Operating income / revenue.
Net margin
-53.3%
Net income / revenue.
Operating cash flow margin
-69.3%
Cash from operations / revenue.
Return on equity (ROE)
-15.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-13.7%
Net income / average total assets.
Return on invested capital (ROIC)
-31.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
136.6%
Research and development expense / revenue.
SG&A / revenue
81.1%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
12.3%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
449.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
59.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-10.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
148.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
16.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-34.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-10.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
2.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
5.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
36.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.65x
Current assets / current liabilities.
Quick ratio
9.28x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.28x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.63
Revenue / diluted weighted shares.
Operating cash flow per share
-$1.13
Cash from operations / diluted weighted shares.
Book value per share
$6.73
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.27x
Market cap / revenue.
P/B
0.65x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.65x
Market cap / tangible book value, when positive.
Earnings yield
-23.4%
Net income / market cap (the inverse of P/E).
What was SCYNEXIS INC's revenue in fiscal 2025?
SCYNEXIS INC reported revenue of $20.6M for fiscal 2025, 449.9% higher than the year before.
Was SCYNEXIS INC profitable in fiscal 2025?
No. It reported a net loss of $8.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.